Cross-Sector entity
Royal Bank of Canada is most often covered alongside Morgan Stanley, which appears in 8 of these 20 stories. Across a 28-day span, the pace is roughly 5 stories per week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 4 of those 20, with the remainder spread across 10 other categories.
28 verified stories tracked
Last mentioned: 15h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Royal Bank of Canada is most often covered alongside Morgan Stanley, which appears in 8 of these 20 stories. Across a 28-day span, the pace is roughly 5 stories per week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 4 of those 20, with the remainder spread across 10 other categories. Each carries 2.3 original sources on average. Royal Bank of Canada appears in 20 tracked Cross-Sector stories published from July 28, 2026 through August 24, 2026. Negative sentiment appears in 0% of the tracked stories.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Royal Bank of Canada. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen upgrades both stocks to Hold
Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
NBRHC Foundation recognizes $60,000 grant
North Bay Regional Health Centre Foundation announces RBC Foundation's $60,000 grant to improve accessibility at Mishkikiwan.
Enveric reports quarterly loss
Enveric Biosciences reported EPS of -$0.76 for the quarter.
Q2 2026 earnings release for Lineage and Magnite
Both companies reported earnings after market close: Lineage EPS $0.76 (beat by $0.98), Magnite EPS $0.26 (beat by $0.01).
RBC raises CTNM target to $23
Royal Bank of Canada raised its Contineum target from $22.00 to $23.00 with an Outperform rating.
Contineum reports Q2 results
Contineum reported Q2 EPS of -$0.40, beating consensus by $0.05.
Lineage dividend payment date
Lineage paid quarterly dividend of $0.5325 to shareholders of record on June 30.
Wells Fargo raises Magnite target
Wells Fargo increased price objective from $15 to $21, maintained Equal Weight.
Weiss Ratings reiterates Sell ratings
Weiss Ratings restated a Sell (d-) on CTNM and a Sell (e+) on ENVB.
GrafTech shares trade 2.6% higher
Shares rose to $5.9110 on below-average volume of 206,136 shares, after a prior close of $5.76.
Clinical Catalyst
Anticipated data readouts for sevasemten in Becker Muscular Dystrophy trials.
Lineage dividend record date
Record date for Lineage's quarterly dividend of $0.5325 per share.
Weiss Ratings lowers to sell (e+)
Weiss Ratings lowered GrafTech from sell (d-) to sell (e+).
Three directors execute insider purchases
Philip Fracassa buys 5,000 MBC shares, Paul Koonce buys 500 SR shares, and Frederick Disanto buys 1,000 EML shares, all in open-market transactions.
RBC reaffirms Magnite Outperform
Royal Bank of Canada reiterated an Outperform rating on Magnite shares.
Morgan Stanley raises CTNM target
Morgan Stanley raised its price target on Contineum Therapeutics from $14.00 to $16.00 with an Equal Weight rating.
Eastern reports Q1 2026 earnings
EML delivers $0.11 EPS, missing the $0.50 estimate by $0.39; revenue of $59.68M trails the $67.74M consensus.
Weiss Ratings upgrades Magnite
Weiss Ratings raised Magnite from 'hold (c-)' to 'hold (c)' rating.
Wall Street Zen upgrades to sell
Wall Street Zen upgraded GrafTech from a strong sell rating to a sell rating.
Evercore and Scotiabank issue Magnite updates
Evercore reiterated Outperform with $21 target; Scotiabank raised target from $16 to $17, Sector Outperform.
A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Source: themarketsdaily.com · tickerreport.com
Melbourne, Florida-based Orion180 filed for a Nasdaq IPO under OIG after swinging to $13.5 million net income on $80.1 million revenue in H1 2026. The E&S homeowners insurer reports $601 million in direct written premiums and over 14,000 agents. Underwriters include Goldman Sachs, RBC, and UBS.
Source: insurancejournal.com · Bloomberg
Analysts remain mostly bullish on RTX and GE Vernova after July earnings, lifting price targets to as high as $250 and $1,338 respectively. Friday's gains came on unusually light volume, raising questions about conviction. Finance readers get a breakdown of target upside, valuation, and risk metrics.
Source: tickerreport.com · dailypolitical.com
RBC Foundation's $60,000 Community Spaces Grant will fund wheelchair and stretcher access to Mishkikiwan, North Bay Regional Health Centre's outdoor ceremonial grounds, strengthening culturally safe Indigenous care.
RBC Foundation's $60,000 grant to North Bay Regional Health Centre is a small but strategic community investment under its Canadian ESG and reconciliation commitments, reinforcing brand equity in Northern Ontario.
Source: thesudburystar.com · saultstar.com
Single-family rental REIT American Homes 4 Rent has a modestly reduced $38 price target from Morgan Stanley, still above a $36.78 consensus and leaving 11% upside. The maintained Overweight rating reinforces the resilience of the SFR asset class amid housing supply constraints.
Morgan Stanley trimmed its American Homes 4 Rent target to $38 from $38.50 while keeping an Overweight rating, against a $36.78 consensus and Moderate Buy average. Equity research actions from Jefferies, UBS, RBC, Mizuho, and Compass Point reveal a broadly constructive but price-sensitive stance on the REIT.
Source: themarketsdaily.com · tickerreport.com
GrafTech's 2.6% daily rise obscures deeper weakness: analyst downgrades, an EPS miss of $0.80, and a market cap of just $154M. For supply chain professionals, the move is a reminder to watch graphite electrode pricing and supplier financial health.
Source: tickerreport.com · dailypolitical.com
Camping World (CWH) saw a rare sell-to-hold upgrade from Wall Street Zen, with analysts maintaining a consensus price target of $12.02—95% above the $6.16 stock price. For retail investors, the call may signal a bottom in RV demand despite a recent revenue miss.
Wall Street Zen upgraded ZipRecruiter from hold to buy, driving the stock 32% above its 50-day moving average to $5.05. Despite the bullish call, overall analyst consensus remains Reduce, and an EVP sold $33,000 in shares, highlighting mixed signals for HR tech.
On August 8, 2026, Wall Street Zen simultaneously upgraded five stocks from energy to retail, moving a combined market cap of $81.8 billion. The moves highlight a potential shift in analyst sentiment and sector rotation as Q2 earnings season winds down.
Source: tickerreport.com · dailypolitical.com
Lineage, a leading cold storage REIT, reported a massive EPS beat but negligible revenue growth, highlighting softness in food logistics demand. The negative dividend payout ratio raises sustainability questions for income-focused investors.
Magnite's Q2 adtech earnings surpassed estimates, driven by 11.3% revenue growth, robust net margins of 21.96%, and a strong analyst consensus. The stock dip belies underlying platform health and CTV momentum.
Two disparate earnings beats: Lineage posted a massive $0.98 EPS surprise but carries negative margins, while Magnite delivered a smaller beat with solid profitability. The comparison reveals risks in chasing headline beats and highlights valuation disconnects.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
CPKC's Q2 earnings beat, with revenue up 12.6% to $2.93 billion, highlights robust cross-border rail demand. For supply chain professionals, the performance reflects strong trade flows and network integration benefits post-merger.
Canadian Pacific Kansas City posted a $0.03 EPS beat and 12.6% revenue growth, maintaining strong margins. With a consensus Buy rating and price targets as high as $105, the stock offers a defensive growth story for investors.
Source: themarketsdaily.com · dailypolitical.com
Sun Communities’ FY 2026 EPS guidance of $6.94–$7.10, surpassing consensus, signals resilience in manufactured housing REITs. The update, alongside a massive Q2 loss, highlights the need for operational technology to improve asset performance and expense control.
Sun Communities’ FY 2026 EPS guidance of $6.94–$7.10 beat the $6.93 consensus, but shares fell 0.4% on heavy volume as revenue guidance was absent. Analyst targets average $140.05, suggesting 15% upside from $121.30 despite recent price target cuts.
Source: MarketBeat · themarketsdaily.com
